(Q38450392)

3 September 2017

title

Oncolytic and immunotherapeutic vaccinia induces antibody-mediated complement-dependent cancer cell lysis in humans (English)

1 reference

3 September 2017

1 reference

1 reference

10

John C Bell

1 reference

3 September 2017

6

Mong Cho

1 reference

3 September 2017

Mi Kyung Kim

1

1 reference

3 September 2017

Caroline J Breitbach

2

1 reference

3 September 2017

Anne Moon

3

1 reference

3 September 2017

Jeong Heo

4

1 reference

3 September 2017

Yu Kyoung Lee

5

1 reference

3 September 2017

Jun Woo Lee

7

1 reference

3 September 2017

Seong-Geun Kim

8

1 reference

3 September 2017

Dae Hwan Kang

9

1 reference

3 September 2017

Byeong Ho Park

11

1 reference

3 September 2017

David H Kirn

12

1 reference

3 September 2017

Tae-Ho Hwang

13

1 reference

3 September 2017

language of work or name

English

0 references

publication date

1 May 2013

1 reference

Science Translational Medicine

3 September 2017

published in

1 reference

3 September 2017

volume

5

1 reference

3 September 2017

issue

185

1 reference

3 September 2017

page(s)

185ra63

1 reference

Novel cancer immunotherapy agents with survival benefit: recent successes and next steps

3 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3005361

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3005361

Ipilimumab plus dacarbazine for previously untreated metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3005361

Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3005361

Clinical development of gene therapy for colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3005361

Why did p53 gene therapy fail in ovarian cancer?

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3005361

Cancer gene therapy: fringe or cutting edge?

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3005361

Cancer immunotherapy: moving beyond current vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3005361

Pilot study of vaccination with recombinant CEA-MUC-1-TRICOM poxviral-based vaccines in patients with metastatic carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3005361

ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3005361

Getting oncolytic virus therapies off the ground

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3005361

Oncolytic virotherapy: approaches to tumor targeting and enhancing antitumor effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3005361

Clinical trial results with oncolytic virotherapy: a century of promise, a decade of progress

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3005361

Replication-selective virotherapy for cancer: Biological principles, risk management and future directions

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3005361

Reovirus therapy of tumors with activated Ras pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3005361

Exploiting tumor-specific defects in the interferon pathway with a previously unknown oncolytic virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3005361

VSV strains with defects in their ability to shutdown innate immunity are potent systemic anti-cancer agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3005361

An adenovirus mutant that replicates selectively in p53-deficient human tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3005361

Attenuated multi–mutated herpes simplex virus–1 for the treatment of malignant gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3005361

Translation of targeted oncolytic virotherapeutics from the lab into the clinic, and back again: a high-value iterative loop.

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3005361

Systemic efficacy with oncolytic virus therapeutics: clinical proof-of-concept and future directions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3005361

Systemic armed oncolytic and immunologic therapy for cancer with JX-594, a targeted poxvirus expressing GM-CSF.

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3005361

Immune-mediated antitumor activity of reovirus is required for therapy and is independent of direct viral oncolysis and replication

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3005361

Induction of strong antitumor immunity by an HSV-2-based oncolytic virus in a murine mammary tumor model

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3005361

Targeting of interferon-beta to produce a specific, multi-mechanistic oncolytic vaccinia virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3005361

Targeted and armed oncolytic poxviruses: a novel multi-mechanistic therapeutic class for cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3005361

Intravenous delivery of a multi-mechanistic cancer-targeted oncolytic poxvirus in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3005361

Enhancing poxvirus oncolytic effects through increased spread and immune evasion

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3005361

Persistent Toll-like receptor signals are required for reversal of regulatory T cell-mediated CD8 tolerance

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3005361

Innate immunity against vaccinia virus is mediated by TLR2 and requires TLR-independent production of IFN-beta

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3005361

Toll-like receptor 8-mediated activation of murine plasmacytoid dendritic cells by vaccinia viral DNA

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3005361

Use of a targeted oncolytic poxvirus, JX-594, in patients with refractory primary or metastatic liver cancer: a phase I trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3005361

Complement. First of two parts

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3005361

Complement activation determines the therapeutic activity of rituximab in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3005361

Rituximab (anti-CD20) therapy of B-cell lymphomas: direct complement killing is superior to cellular effector mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3005361

A polymorphism in the complement component C1qA correlates with prolonged response following rituximab therapy of follicular lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3005361

Ofatumumab is more efficient than rituximab in lysing B chronic lymphocytic leukemia cells in whole blood and in combination with chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3005361

rILYd4, a human CD59 inhibitor, enhances complement-dependent cytotoxicity of ofatumumab against rituximab-resistant B-cell lymphoma cells and chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3005361

Ofatumumab is active in patients with fludarabine-refractory CLL irrespective of prior rituximab: results from the phase 2 international study

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3005361

Rational strain selection and engineering creates a broad-spectrum, systemically effective oncolytic poxvirus, JX-963

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3005361

Modified model of VX2 tumor overexpressing vascular endothelial growth factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3005361

Identification of tumor-associated antigens by using SEREX in hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3005361

More than markers: biological significance of cancer stem cell-defining molecules

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3005361

Associations between leptin and adiponectin receptor upregulation, visceral obesity and tumour stage in oesophageal and junctional adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3005361

Intracellular tumor-associated antigens represent effective targets for passive immunotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3005361

Targeted inflammation during oncolytic virus therapy severely compromises tumor blood flow

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3005361

Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3005361

Oncolytic and immunostimulatory efficacy of a targeted oncolytic poxvirus expressing human GM-CSF following intravenous administration in a rabbit tumor model

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3005361

Concomitant activation of the JAK/STAT, PI3K/AKT, and ERK signaling is involved in leptin-mediated promotion of invasion and migration of hepatocellular carcinoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3005361

CD24 is a novel predictor for poor prognosis of hepatocellular carcinoma after surgery

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3005361

Gene deletions and amplifications in human hepatocellular carcinomas: correlation with hepatocyte growth regulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3005361

Molecular cloning and characterization of LAPTM4B, a novel gene upregulated in hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3005361

Sirtuins: critical regulators at the crossroads between cancer and aging

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3005361

Characterization of a human gene with sequence homology to Saccharomyces cerevisiae SIR2

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3005361

Mig6 is a negative regulator of EGF receptor-mediated skin morphogenesis and tumor formation

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3005361

Whole-genome sequencing of liver cancers identifies etiological influences on mutation patterns and recurrent mutations in chromatin regulators

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3005361

Analysis of the HLA class I associated peptide repertoire in a hepatocellular carcinoma cell line reveals tumor-specific peptides as putative targets for immunotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3005361

RECQL, a member of the RecQ family of DNA helicases, suppresses chromosomal instability.

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3005361

Consensus genes of the literature to predict breast cancer recurrence.

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3005361

Hypoxia-inducible adenosine A2B receptor modulates proliferation of colon carcinoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3005361

Tumor HLA-DR expression linked to early intrahepatic recurrence of hepatocellular carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3005361

10.1126/SCITRANSLMED.3005361

21 January 2018

Identifiers

DOI

1 reference

release_64kyhje5z5cr5ovreos6s5c4a4

3 September 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/64kyhje5z5cr5ovreos6s5c4a4

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference